DSpace Collection:http://sgc.anlis.gob.ar/handle/123456789/252026-05-20T02:52:08Z2026-05-20T02:52:08ZDiagnostic performance of the TR chagas bio-manguinhos rapid test for detecting anti-Trypanosoma cruzi IgG in human samples from three Southern Cone countriesDe Carvalho Medrado Vasconcelos, LarissaOssowski, Micaela SoledadDomingos Silva, EdimilsonDias Sampaio, DanielSabaini Pavan, Tycha BiancaViana Ferreira, Randrin QueirozSilva Santos de Jesus, FelipeChadi, RaúlFernández, Marisa LilianaHernández, YolandaGómez, Karina AndreaNeves Santos, Fred Lucianohttp://sgc.anlis.gob.ar/handle/123456789/27452026-05-14T18:46:10Z2026-05-08T00:00:00ZTitle: Diagnostic performance of the TR chagas bio-manguinhos rapid test for detecting anti-Trypanosoma cruzi IgG in human samples from three Southern Cone countries
Authors: De Carvalho Medrado Vasconcelos, Larissa; Ossowski, Micaela Soledad; Domingos Silva, Edimilson; Dias Sampaio, Daniel; Sabaini Pavan, Tycha Bianca; Viana Ferreira, Randrin Queiroz; Silva Santos de Jesus, Felipe; Chadi, Raúl; Fernández, Marisa Liliana; Hernández, Yolanda; Gómez, Karina Andrea; Neves Santos, Fred Luciano
Abstract: Chagas disease (CD) remains a major public health challenge in Latin America, largely due to persistent underdiagnosis, particularly in endemic and resource-limited settings. Rapid diagnostic tests (RDTs) offer a pragmatic approach to expand serological screening; however, their performance varies across epidemiological contexts and parasite genetic backgrounds. The TR Chagas Bio-Manguinhos test, based on recombinant chimeric antigens, has shown high sensitivity in previous evaluations, but data from Southern Cone remain limited. We conducted a cross-sectional diagnostic accuracy study using 311 anonymized human plasma samples obtained in Argentina, including 233 Trypanosoma cruzi-positive and 78 negative samples classified by a composite reference standard based on at least two independent serological assays. Diagnostic performance of the TR Chagas Bio-Manguinhos rapid test was assessed in terms of sensitivity, specificity, accuracy, likelihood ratios, diagnostic odds ratio, and agreement. Sensitivity was further stratified by country of origin (Argentina, Bolivia, Paraguay) and by cardiac involvement according to the Kuschnir classification. The TR Chagas Bio-Manguinhos test demonstrated high overall performance, with a sensitivity of 97.0% (95% CI: 93.9-98.5%), specificity of 94.9% (95% CI: 87.5-98.0%), and accuracy of 96.5% (95% CI: 93.8-98.0%). Agreement with the reference standard was almost perfect (κ = 0.91). Sensitivity remained consistently high across geographical origins and Kuschnir cardiac stages, with no statistically significant differences between subgroups. The negative likelihood ratio (0.03) indicated strong ability to rule out infection. These findings provide the first independent evidence supporting the high performance of the TR Chagas Bio-Manguinhos test in people from Argentina, Bolivia and Paraguay. The combination of very high sensitivity and robust specificity supports its use as a frontline serological screening tool for chronic T. cruzi infection in the Southern Cone, provided that reactive results are subsequently confirmed by laboratory- based assays in accordance with international guidelines.
Description: Fil: De Carvalho Medrado Vasconcelos, Larissa. Advanced Public Health Laboratory (LASP), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil; Interdisciplinary Research Group in Biotechnology and Epidemiology of Infectious Diseases (GRUPIBE), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil.
Fil: Ossowski, Micaela Soledad. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" (INGEBI-CONICET), Buenos Aires, Argentina.
Fil: Domingos Silva, Edimilson. Immunobiological Technology Institute (Bio-Manguinhos), Oswaldo Cruz Foundation (FIOCRUZ-RJ), Rio de Janeiro, Rio de Janeiro, Brazil.
Fil: Dias Sampaio, Daniel. Interdisciplinary Research Group in Biotechnology and Epidemiology of Infectious Diseases (GRUPIBE), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil.
Fil: Sabaini Pavan, Tycha Bianca. Advanced Public Health Laboratory (LASP), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil; Interdisciplinary Research Group in Biotechnology and Epidemiology of Infectious Diseases (GRUPIBE), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil.
Fil: Viana Ferreira, Randrin Queiroz. Advanced Public Health Laboratory (LASP), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil; Interdisciplinary Research Group in Biotechnology and Epidemiology of Infectious Diseases (GRUPIBE), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil.
Fil: Silva Santos de Jesus, Felipe. Advanced Public Health Laboratory (LASP), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil; Interdisciplinary Research Group in Biotechnology and Epidemiology of Infectious Diseases (GRUPIBE), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil.
Fil: Chadi, Raúl. Hospital General de Agudos "Dr. Ignacio Pirovano", Buenos Aires, Argentina.
Fil: Fernández, Marisa Liliana. Instituto Nacional de Parasitología "Dr. Mario Fatala Chabén", Buenos Aires, Argentina.
Fil: Hernández, Yolanda. Instituto Nacional de Parasitología "Dr. Mario Fatala Chabén", Buenos Aires, Argentina.
Fil: Gómez, Karina Andrea. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" (INGEBI-CONICET), Buenos Aires, Argentina.
Fil: Neves Santos, Fred Luciano. Advanced Public Health Laboratory (LASP), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil; Interdisciplinary Research Group in Biotechnology and Epidemiology of Infectious Diseases (GRUPIBE), Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ-BA), Salvador, Bahia, Brazil; Integrated Translational Program in Chagas Disease from FIOCRUZ (Fio-Chagas), Oswaldo Cruz Foundation (FIOCRUZ-RJ), Rio de Janeiro, Rio de Janeiro, Brazil.2026-05-08T00:00:00ZMammal ectoparasites in the Global South: Climate-driven threats to human and other animal healthLeonardi, Maria SoledadSanchez, Juliana PLaroche, MaureenWeeks, Emmahttp://sgc.anlis.gob.ar/handle/123456789/27392026-05-07T14:58:15Z2026-01-01T00:00:00ZTitle: Mammal ectoparasites in the Global South: Climate-driven threats to human and other animal health
Authors: Leonardi, Maria Soledad; Sanchez, Juliana P; Laroche, Maureen; Weeks, Emma2026-01-01T00:00:00ZTrypanosoma cruzi Secreted Cyclophilin TcCyP19 as an Early Marker for Trypanocidal Treatment EfficiencyPerrone, Alina E.Pinillo, MarianaRial, Marcela SilvinaFernandez, MarisaMilduberger, NataliaGonzález, CarolinaBustos, Patricia L.Fichera, Laura E.Laucella, Susana A.Albareda, María CeciliaBua, Jacquelinehttp://sgc.anlis.gob.ar/handle/123456789/27322026-03-19T15:10:23Z2023-07-25T00:00:00ZTitle: Trypanosoma cruzi Secreted Cyclophilin TcCyP19 as an Early Marker for Trypanocidal Treatment Efficiency
Authors: Perrone, Alina E.; Pinillo, Mariana; Rial, Marcela Silvina; Fernandez, Marisa; Milduberger, Natalia; González, Carolina; Bustos, Patricia L.; Fichera, Laura E.; Laucella, Susana A.; Albareda, María Cecilia; Bua, Jacqueline
Abstract: Cyclophilins (CyPs) are a family of enzymes involved in protein folding. Trypanosoma
cruzi, the causative agent of Chagas disease, has a 19-kDa cyclophilin, TcCyP19, that was found to be
secreted in parasite stages of the CL Brener clone and recognized by sera from T. cruzi-infected mice
and patients. The levels of specific antibodies against TcCyP19 in T. cruzi-infected mice and subjects
before and after drug treatment were measured by an in-house enzyme linked immunosorbent assay
(ELISA). Mice in the acute and chronic phase of infection, with successful trypanocidal treatments,
showed significantly lower anti-TcCyP19 antibody levels than untreated mice. In children and adults
chronically infected with T. cruzi, a significant decrease in the anti-TcCyP19 titers was observed
after 12 months of etiological treatment. This decrease was maintained in adult chronic patients
followed-up 30–38 months post-treatment. These results encourage further studies on TcCyP19 as an
early biomarker of trypanocidal treatment efficiency.2023-07-25T00:00:00ZEconomic burden of Chagas disease in Latin American countries: a population-based cost-of-illness analysis from the RAISE studyViegas Andrade, Monicade Souza Noronha, Kenya Valeria Micaelade Souza, AlineAbreu Julião. NayaraMotta-Santos, André SoaresFranco Braga, Paulo EstevãoBracarense, HenriqueAlves do Santos, André BatistaRamos Nascimento, BrunoMachado,Ísis EloahMartins-Melo, Francisco RogerlândioMolina, IsraelPerel, PabloGeissbühler, YvonneDemacq, CarolineCastro Jaramillo, Hector EduardoEcheverria, Luis EPrincipato, Mario BrunoAguilera Mora, Luisa FernandaFernandez, MarisaNina Calisaya, Jhonatan JhimmyPinho Ribeiro, Antonio Luizhttp://sgc.anlis.gob.ar/handle/123456789/27122026-02-25T16:34:19Z2026-02-01T00:00:00ZTitle: Economic burden of Chagas disease in Latin American countries: a population-based cost-of-illness analysis from the RAISE study
Authors: Viegas Andrade, Monica; de Souza Noronha, Kenya Valeria Micaela; de Souza, Aline; Abreu Julião. Nayara; Motta-Santos, André Soares; Franco Braga, Paulo Estevão; Bracarense, Henrique; Alves do Santos, André Batista; Ramos Nascimento, Bruno; Machado,Ísis Eloah; Martins-Melo, Francisco Rogerlândio; Molina, Israel; Perel, Pablo; Geissbühler, Yvonne; Demacq, Caroline; Castro Jaramillo, Hector Eduardo; Echeverria, Luis E; Principato, Mario Bruno; Aguilera Mora, Luisa Fernanda; Fernandez, Marisa; Nina Calisaya, Jhonatan Jhimmy; Pinho Ribeiro, Antonio Luiz
Abstract: Background Chagas disease (ChD) remains a public health concern in Latin America. Despite a decline in overall
prevalence, the chronic symptomatic forms still impose a substantial epidemiological and economic burden. This
study undertakes a comprehensive, population-based cost analysis of chronic Chagas disease (CCD) from a societal
perspective in seven endemic Latin American countries for 2010 and 2023.
Methods A Markov model with one-year cycles and six states was employed. Direct medical and indirect costs,
converted to 2024 purchasing power parity US dollars, were estimated using prevalence data from the Global
Burden of Disease Study 2023. Based on a previous Brazilian Markov model, parameters were adjusted using
healthcare coverage and per capita health expenditure ratios for each country, further validated by national
experts.
Findings In 2010, Brazil (US$252 billion) and Argentina (US$164 billion) had the highest lifetime burdens. As a
percentage of annual Gross Domestic Product, Bolivia (0⋅9%) and Argentina (0⋅8%) were most affected. CCD
accounted for 6% of total health expenditures in both countries. Between 2010 and 2023, most countries experienced
a decline in economic burden due to decreased CCD prevalence, despite an increased proportion of patients with
cardiac conditions, reflecting population aging and disease progression2026-02-01T00:00:00Z